July 15, 2019
The Alzheimer's Drug Discovery Foundation (ADDF) released a new clinical trial analysis report that shows researchers are now developing drugs for various targets associated with aging biology – moving beyond traditional amyloid and tau approaches.
May 31, 2019
The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.
May 30, 2019
The first four awards from the first request for proposals total up to approximately $3.5 million.
April 2, 2019
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
March 21, 2019
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
January 14, 2019
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
January 3, 2019
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
September 24, 2018
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
September 21, 2018
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
July 17, 2018
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.